Centre Hospitalier Regional Et Universitaire De Lille (Chru)

Universite Du Littoral Cote D'opale

Taipei Medical University

Université De Lille 2 Droit Et Santé

Institut National De La Sante Et De La Recherche Medicale

Université De Lille

Inserm (Institut National De La Sante Et De La Recherche Medicale)

Centre Hospitalier Régional Et Universitaire De Lille

Inserm

David Devos

Jean-christophe Devedjian

Thierry Burnouf

Ming-Li Chou

Charlotte Laloux

Caroline Moreau

Flore Gouel

Jean-Christophe Devedjian

A process for preparing a modified heat-treated platelet pellet lysate, said process comprising the steps of: a) Providing a platelet pellet lysate, b) Heat-treating the platelet pellet lysate at a temperature of 55° C. to 65° C. during 20 to 40 minutes, c) Purifying the heat-treated platelet pellet lysate of step b) so as to obtain a modified heat treated platelet pellet lysate having a total protein content of less than 70% of the total protein content of the platelet pellet lysate of step a).

Preparation of platelet pellet lysate and its use for treating neurological disorders

Process for preparing a heat-treated pooled human platelet lysate, said process comprising the steps of: a) Providing a pooled human platelet lysate (p HPL), b) Heat-treating the pooled human platelet lysate at a temperature of 50&#xb0; C. to 70&#xb0; C. during 20 to 40 minutes, c) Purifying the heat-treated pooled human platelet lysate of step b).

Process for preparing a pooled human platelet lysate, pooled human platelet lysate and its use for treating neurological disorders

The present invention is directed to pharmaceutical solution comprising at least dopamine for use in treating Parkinson's disease, wherein said pharmaceutical solution is kept under anaerobic conditions from its formulation to its administration.

Pharmaceutical solution comprising dopamine for use in treating parkinson's disease

Growing community of inventors

Lille, France

David Devos